Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

SIMPLE SUMMARY: The use of venetoclax combined with hypomethylating agents or low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia unfit for intensive chemotherapy was recently approved. However, the evidence in relapse or refractory patients is still scarce. The cohort of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Labrador, Jorge, Saiz-Rodríguez, Miriam, de Miguel, Dunia, de Laiglesia, Almudena, Rodríguez-Medina, Carlos, Vidriales, María Belén, Pérez-Encinas, Manuel, Sánchez-Sánchez, María José, Cuello, Rebeca, Roldán-Pérez, Alicia, Vives, Susana, Benzo-Callejo, Gonzalo, Colorado, Mercedes, García-Fortes, María, Sayas, María José, Olivier, Carmen, Recio, Isabel, Conde-Royo, Diego, Bienert-García, Álvaro, Vahi, María, Muñoz-García, Carmen, Seri-Merino, Cristina, Tormo, Mar, Vall-llovera, Ferran, Foncillas, María-Ángeles, Martínez-Cuadrón, David, Sanz, Miguel Ángel, Montesinos, Pau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997036/
https://www.ncbi.nlm.nih.gov/pubmed/35406512
http://dx.doi.org/10.3390/cancers14071734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997036/
https://www.ncbi.nlm.nih.gov/pubmed/35406512
http://dx.doi.org/10.3390/cancers14071734

Ejemplares similares